You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.


( LEN-a-LID-o-mide )
Exceptional Access Program
  • lenalidomide - Anemia due to MDS, with specific criteria
  • lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following autologous stem-cell transplantation, according to specific criteria.
  • lenalidomide - Treatment of multiple myeloma in combination with dexamethasone in patients who are not candidates
    for autologous stem cell transplant, with specific criteria
  • lenalidomide - In combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma
  • lenalidomide - For the treatment of patients with multiple myeloma with good performance status who have received at least one prior therapy.
Other Name(s): Revlimid®
Appearance: capsule in various strengths

You might also be interested in